Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Metabolism: Clinical and Experimental

• Publication date

  2002-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/META.2002.34700PMID 12200754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

  2000cited by this paper
• Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

  1999cited by this paper
• Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

  1998cited by this paper
• Glucagon-Like Peptides

  1998cited by this paper
• Renal glucose production and utilization: new aspects in humans

  1997cited by this paper
• Assessment of Hepatic Sensitivity to Glucagon in NIDDM: Use as a Tool to Estimate the Contribution of the Indirect Pathway to Nocturnal Glycogen Synthesis

  1997cited by this paper
• Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance

  1997cited by this paper
• Isolation of glucagon antagonists by random molecular mutagenesis and screening.

  1993cited by this paper
• Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study.

  1992cited by this paper
• Hepatic glucagon sensitivity and fasting glucose concentration in normal dogs.

  1992cited by this paper
• Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

  1992cited by this paper
• Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients

  1991cited by this paper
• Glucose turnover and recycling in diabetes secondary to total pancreatectomy: effect of glucagon infusion.

  1990cited by this paper
• Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans.

  1990cited by this paper
• Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.

  1990cited by this paper
• Hepatic glucose production in insulin-resistant states.

  1989cited by this paper
• Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

  1989cited by this paper
• Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

  1989cited by this paper
• The disposal of an oral glucose load in patients with non-insulin-dependent diabetes.

  1988cited by this paper
• Hyperglucagonemia and insulin-mediated glucose metabolism.

  1987cited by this paper
• Similar Dose Responsiveness of Hepatic Glycogenolysis and Gluconeogenesis to Glucagon In Vivo

  1987cited by this paper
• Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.

  1987cited by this paper
• Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics

  1987cited by this paper
• Abnormal Glucose Modulation of Islet A- and B-Cell Responses to Arginine in Non-insulin-dependent Diabetes Mellitus

  1985cited by this paper
• Counterregulatory Hormone Release and Glucose Recovery After Hypoglycemia in Non-insulin-dependent Diabetic Patients

  1983cited by this paper
• Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy

  1983cited by this paper
• Minimal Increases in Glucagon Levels Enhance Glucose Production in Man with Partial Hypoinsulinemia

  1983cited by this paper
• Transient hepatic response to glucagon in man: role of insulin and hyperglycemia.

  1982cited by this paper
• Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus.

  1978cited by this paper
• Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes.

  1978cited by this paper
• Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

  1977cited by this paper
• The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog.

  1976cited by this paper
• Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects.

  1976cited by this paper
• Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.

  1976cited by this paper
• Arginine-Stimulated Hyperglucagonemia in Diabetic Pima Indians

  1976cited by this paper
• Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus.

  1975cited by this paper
• Studies of pancreatic alpha cell function in normal and diabetic subjects.

  1970cited by this paper
• Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver.

  1966cited by this paper
• EFFECT OF VERY SMALL CONCENTRATIONS OF INSULIN ON FOREARM METABOLISM. PERSISTENCE OF ITS ACTION ON POTASSIUM AND FREE FATTY ACIDS WITHOUT ITS EFFECT ON GLUCOSE.

  1964cited by this paper
• Measurement of size and turnover rate of body glucose pool by the isotope dilution method.

  1956cited by this paper

• Glucagon: The Arab Phoenix of the Complex Pathophysiology of Type 2 Diabetes.

  2025cites this paper
• Ethnicity‐related differences in mitochondrial regulation by insulin stimulation in diabetes

  2024cites this paper
• Small molecules targeting selective PCK1 and PGC-1α lysine acetylation cause anti-diabetic action through increased lactate oxidation.

  2024cites this paper
• Perfecting the Puzzle of Pathophysiology: Exploring Combination Therapy in the Treatment of Type 2 Diabetes

  2023cites this paper
• Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice

  2023cites this paper
• High doses of exogenous glucagon stimulate insulin secretion and reduce insulin clearance in healthy humans.

  2023cites this paper
• Upregulated TGF-β1 contributes to hyperglycaemia in type 2 diabetes by potentiating glucagon signalling

  2023cites this paper
• MODERN CONCEPTS OF THE PATHOGENESIS OF TYPE 2 DIABETES MELLITUS

  2022cites this paper
• The Effect of Glucagon on Protein Catabolism During Insulin Deficiency - Exchange of Amino acids Across Skeletal Muscle and The Splanchnic Bed.

  2022cites this paper
• Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes.

  2021cites this paper
• CONTEMPORARY APPROACHES IN INSULIN ADMINISTRATION FOR THE TREATMENT OF DIABETES

  2021cites this paper
• Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice

  2021cites this paper
• Glucagon Clearance is Preserved in Type 2 Diabetes.

  2021cites this paper
• S1P Signaling Pathways in Pathogenesis of Type 2 Diabetes

  2021cites this paper
• Mathematical model of blood glucose dynamics by emulating the pathophysiology of glucose metabolism in type 2 diabetes mellitus

  2020cites this paper
• Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

  2019cites this paper
• Dapagliflozin improves hepatic injury and pancreatic endoplasmic reticulum stress but induces hepatic gluconeogenic enzymes expression in obese rats.

  2019cites this paper
• Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications.

  2019cites this paper
• Dietary habits contribute to define the risk of type 2 diabetes in humans.

  2019cites this paper
• Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy

  2019cites this paper
• Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy - A Retrospective Observational Study.

  2019cites this paper
• Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues

  2019cites this paper
• Pathophysiology of Type 2 Diabetes

  2019cites this paper
• GPR119 Agonism Increases Glucagon Secretion During Insulin-Induced Hypoglycemia

  2018cites this paper
• Treatment approach to type 2 diabetes: Past, present and future

  2018cites this paper
• Amendment history : Corrigendum ( May 2014 ) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

  2018cites this paper
• Metabolic effects of glucagon in humans

  2018influential citation
• Effets de deux modalités d'entraînement et d'une complémentation à base d'extraits végétaux sur le développement du diabète de type 2 : Physiologie

  2018cites this paper
• Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

  2018cites this paper
• SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

  2017cites this paper
• A first‐in‐human pharmacodynamic and pharmacokinetic study of a fully human anti‐glucagon receptor monoclonal antibody in normal healthy volunteers

  2017cites this paper
• Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor

  2017cites this paper
• Modeling Pharmacokinetics and Pharmacodynamics of Glucagon for Simulation of the Glucoregulatory System in Patients with Type 1 Diabetes.

  2017cites this paper
• Midgut-Derived Activin Regulates Glucagon-like Action in the Fat Body and Glycemic Control.

  2017cites this paper
• Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes

  2017cites this paper
• Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm

  2017cites this paper
• Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.

  2017cites this paper
• Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes

  2017cites this paper
• Targeting hepatic glucose metabolism in the treatment of type 2 diabetes

  2016cites this paper
• Investigating the relative contribution of obesity and glucose in the development of β-cell dysfunction

  2016cites this paper
• Bariatric surgery and type 2 diabetes: are there weight loss‐independent therapeutic effects of upper gastrointestinal bypass?

  2016cites this paper
• Mortality reduction among persons with type 2 diabetes: (-)-Epicatechin as add-on therapy to metformin?

  2016cites this paper
• Sexual Dimorphism in Hepatic, Adipose Tissue, and Peripheral Tissue Insulin Sensitivity in Obese Humans

  2015cites this paper
• Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

  2015cites this paper
• Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block

  2015cites this paper
• Type 2 diabetes mellitus

  2015cites this paper
• First proof of pharmacology in humans of a novel glucagon receptor antisense drug

  2015cites this paper
• Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus

  2015cites this paper
• 25. Pathogenesis of type 2 diabetes mellitus

  2015cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• Editorial. Pathophysiology of Type 2 Diabetes: The Long Journey into Present

  2015cites this paper
• Glucagon--Early breakthroughs and recent discoveries.

  2015cites this paper
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

  2015cites this paper
• The association of DNA methylation patterns in TCF7L2 and GIPR genes with Type 2 Diabetes

  2014cites this paper
• Novel Agents for the Treatment of Type 2 Diabetes

  2014cites this paper
• Characterization of a Standardized Glucagon Challenge Test as a Pharmacodynamic Tool in Pharmacological Research

  2014cites this paper
• Clinical implication of SGLT2 inhibitors in type 2 diabetes

  2014cites this paper
• Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

  2014cites this paper
• Protein Degradative Processes Associated with Anabolic Dysregulation in Diabetic Skeletal Muscle

  2014cites this paper
• Clinical implication of SGLT2 inhibitors in type 2 diabetes

  2014cites this paper
• Mechanisms of insulin resistance and β - cell failure in type 2 diabetes. Effective diet against o minous octet

  2013cites this paper
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Personalized Management of Hyperglycemia in Type 2 Diabetes

  2013cites this paper
• Diabetes mellitus e tolerância à glicose diminuída na população adulta urbana do município de Campo Grande (MS)

  2013cites this paper
• Alteration of De Novo Glucose Production Contributes to Fasting Hypoglycaemia in Fyn Deficient Mice

  2013cites this paper
• Intra-islet glucagon secretion and action in the regulation of glucose homeostasis

  2013cites this paper
• ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study

  2012cites this paper
• Lentivirus shRNA Grb10 targeting the pancreas induces apoptosis and improved glucose tolerance due to decreased plasma glucagon levels

  2012cites this paper
• Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study

  2011cites this paper
• The role of dysregulated glucagon secretion in type 2 diabetes

  2011cites this paper
• Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.

  2010cites this paper
• Glucose Suppression of Glucagon Secretion

  2010cites this paper
• A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.

  2009cites this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cites this paper
• złowieszczego oktetu ” : nowy model leczenia cukrzycy typu 2 From the triumvirate to the „ ominous octet ” : a new paradigm for the treatment of type 2 diabetes mellitus

  2009cites this paper
• A rosiglitazone-induced increase in plasma adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy 8

  2008cites this paper
• Contribution of defects in glucose production and uptake to carbohydrate intolerance in insulin-resistant subjects.

  2008cites this paper
• Effects of low‐dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes

  2007cites this paper
• New Insights on the Regulation of Glucagon Secretion from Islet Alpha Cells and its Importance in Diabetes

  2006cites this paper
• Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus

  2006cites this paper
• Complement C3 is a risk factor for the development of diabetes: a population-based cohort study.

  2005cites this paper
• Effects of vanadate on glucose production in cultured hepatocytes isolated from rats on high saturated fat diet.

  2005cites this paper
• Complement C 3 Is a Risk Factor for the Development of Diabetes A Population-Based Cohort Study

  2005cites this paper
• Ghrelin Is Suppressed by Glucagon and Does Not Mediate Glucagon-Related Growth Hormone Release

  2005cites this paper
• Progress towards glucagon receptor antagonist therapy for Type 2 diabetes

  2005cites this paper
• Aplicación de la farmacogenómica en las acciones del hepatocito relacionadas con el metabolismo de la glucosa (2º Artículo)

  2005cites this paper
• Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes

  2004cites this paper
• Dysfunctional fat cells, lipotoxicity and type 2 diabetes

  2004cites this paper
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

  2004cites this paper
• Pathogenesis of type 2 diabetes mellitus.

  2004cites this paper
• Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes.

  2004cites this paper
• Metabolic and Molecular Pathogenesis of Type 2 Diabetes Mellitus

  2003cites this paper
• Metabolic and molecular basis of insulin resistance

  2003cites this paper
• Midgut-Derived Activin Re gulates Glucagon-like Action in the Fat Body and Glycemic Control Graphical Abstract Highlights

  year unknowncites this paper